These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

643 related articles for article (PubMed ID: 25563369)

  • 21. Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.
    Dirican E; Kaya Z; Gullu G; Peker I; Ozmen T; Gulluoglu BM; Kaya H; Ozer A; Akkiprik M
    Asian Pac J Cancer Prev; 2014; 15(21):9327-33. PubMed ID: 25422220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas.
    Barbareschi M; Buttitta F; Felicioni L; Cotrupi S; Barassi F; Del Grammastro M; Ferro A; Dalla Palma P; Galligioni E; Marchetti A
    Clin Cancer Res; 2007 Oct; 13(20):6064-9. PubMed ID: 17947469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PIK3CA Mutations in Resected Small Cell Lung Cancer.
    Han N; Cheng QY; Chen B; Cai JF; Wang XJ; Lou CJ; Qin J; Ye WW; Lei L; Lu HY
    Adv Clin Exp Med; 2016; 25(3):397-402. PubMed ID: 27629725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.
    Maruyama N; Miyoshi Y; Taguchi T; Tamaki Y; Monden M; Noguchi S
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):408-14. PubMed ID: 17202311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
    Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
    Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.
    Papaxoinis G; Kotoula V; Alexopoulou Z; Kalogeras KT; Zagouri F; Timotheadou E; Gogas H; Pentheroudakis G; Christodoulou C; Koutras A; Bafaloukos D; Aravantinos G; Papakostas P; Charalambous E; Papadopoulou K; Varthalitis I; Efstratiou I; Zaramboukas T; Patsea H; Scopa CD; Skondra M; Kosmidis P; Pectasides D; Fountzilas G
    PLoS One; 2015; 10(10):e0140293. PubMed ID: 26452060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma.
    Cohen Y; Goldenberg-Cohen N; Shalmon B; Shani T; Oren S; Amariglio N; Dratviman-Storobinsky O; Shnaiderman-Shapiro A; Yahalom R; Kaplan I; Hirshberg A
    Oral Oncol; 2011 Oct; 47(10):946-50. PubMed ID: 21824802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of PIK3CA mutations as a biomarker in Chinese breast carcinomas from Western China.
    Cheng J; Fu S; Wei C; Tania M; Khan MA; Imani S; Zhou B; Chen H; Xiao X; Wu J; Fu J
    Cancer Biomark; 2017; 19(1):85-92. PubMed ID: 28269754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains.
    Redon R; Muller D; Caulee K; Wanherdrick K; Abecassis J; du Manoir S
    Cancer Res; 2001 May; 61(10):4122-9. PubMed ID: 11358835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single-nucleotide polymorphisms in DNA double-strand break repair genes: association with head and neck cancer and interaction with tobacco use and alcohol consumption.
    Werbrouck J; De Ruyck K; Duprez F; Van Eijkeren M; Rietzschel E; Bekaert S; Vral A; De Neve W; Thierens H
    Mutat Res; 2008 Oct; 656(1-2):74-81. PubMed ID: 18768166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer.
    Nichols AC; Black M; Yoo J; Pinto N; Fernandes A; Haibe-Kains B; Boutros PC; Barrett JW
    BMC Pharmacol Toxicol; 2014 Nov; 15():66. PubMed ID: 25428177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.
    Zumsteg ZS; Morse N; Krigsfeld G; Gupta G; Higginson DS; Lee NY; Morris L; Ganly I; Shiao SL; Powell SN; Chung CH; Scaltriti M; Baselga J
    Clin Cancer Res; 2016 Apr; 22(8):2009-19. PubMed ID: 26589432
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation.
    Tinhofer I; Budach V; Saki M; Konschak R; Niehr F; Jöhrens K; Weichert W; Linge A; Lohaus F; Krause M; Neumann K; Endris V; Sak A; Stuschke M; Balermpas P; Rödel C; Avlar M; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; Baumann M;
    Eur J Cancer; 2016 Apr; 57():78-86. PubMed ID: 26896955
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Delineating genetic pathways of disease progression in head and neck squamous cell carcinoma.
    Worsham MJ; Pals G; Schouten JP; Van Spaendonk RM; Concus A; Carey TE; Benninger MS
    Arch Otolaryngol Head Neck Surg; 2003 Jul; 129(7):702-8. PubMed ID: 12874067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.
    Lee JW; Soung YH; Kim SY; Lee HW; Park WS; Nam SW; Kim SH; Lee JY; Yoo NJ; Lee SH
    Oncogene; 2005 Feb; 24(8):1477-80. PubMed ID: 15608678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5-8.
    Hafkamp HC; Speel EJ; Haesevoets A; Bot FJ; Dinjens WN; Ramaekers FC; Hopman AH; Manni JJ
    Int J Cancer; 2003 Nov; 107(3):394-400. PubMed ID: 14506739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma.
    Pedrero JM; Carracedo DG; Pinto CM; Zapatero AH; Rodrigo JP; Nieto CS; Gonzalez MV
    Int J Cancer; 2005 Mar; 114(2):242-8. PubMed ID: 15543611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Relationship of Grade, Stage and Tobacco Usage in Head and Neck Squamous Cell Carcinoma With p53, PIK3CA and MicroRNA Profiles.
    Kiran K; Chowdhury N; Singh A; Malhotra M; Kishore S
    Cureus; 2024 Feb; 16(2):e54737. PubMed ID: 38524071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Correlation between the incidence of PIK3CA mutations in breast cancer and histopathological characteristics of the tumor].
    Mendelová A; Jezková E; Zubor P; Holubeková V; Lasabová Z; Plank L; Danko J
    Ceska Gynekol; 2014 Aug; 79(4):283-8. PubMed ID: 25398149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
    Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK
    Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.